Home/Pipeline/CT-P55

CT-P55

Psoriasis

Phase 3Active

Key Facts

Indication

Psoriasis

Phase

Phase 3

Status

Active

Company

Celltrion

About Celltrion

Celltrion's mission is to promote patient health by making advanced biologics affordable and accessible globally. It has achieved this by evolving from a contract manufacturer into a vertically integrated powerhouse, becoming the world's leading biosimilar producer with a robust pipeline. Its core strategy leverages massive, FDA/EMA-certified manufacturing capacity, a direct global sales network, and a deep R&D pipeline spanning biosimilars and novel biologics to drive growth and secure long-term market leadership.

View full company profile

Therapeutic Areas

Immunology Oncology Autoimmune Diseases Ophthalmology Respiratory

Other Psoriasis Drugs

Drug	Company	Phase	Status
Autoimmune psoriasis candidate	Nyrada	Preclinical	Active
CYPS317	FibroBiologics	Discovery	Active
PEP Biologic™	Intent Biologics	Unknown	Active
DMT410	Dermata Therapeutics	Preclinical	Exploratory
IL23R program	Acellera	Pre-clinical	Hit-to-Lead
Undisclosed Psoriasis Program	Nepsone	Preclinical	Active
TEM-1657 (Topical)	Temisis	Pre-clinical	Active
TEM-1657 (Oral)	Temisis	Pre-clinical	Active
AIM Platform	Phaim Pharma	Pre-clinical	Active
orismilast	UNION therapeutics	Phase 2	Active
Laikangqita Monoclonal Antibody	Livzon Pharmaceutical	NDA	Marketing application accepted and granted priority review
JNJ-77242113	Johnson & Johnson	Phase 3	Active